These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7161698)

  • 1. [In vitro availability of a topical corticosteroid from various vehicles. Attempt at a correlation with an in vivo study].
    Zuber M; Chemtob C; Chaumeil JC
    J Pharm Belg; 1982; 37(6):393-400. PubMed ID: 7161698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and biological experimentation with difluprednate in cream and gel forms in pediatric dermatology].
    Desmons F; Defrenne C
    Lille Med; 1977 Nov; 22(9 Suppl 2):743-5. PubMed ID: 609320
    [No Abstract]   [Full Text] [Related]  

  • 3. [Influence of the stratum corneum on transepidermal water loss and Bioavailability of a new topical steroid, difluprednate: clinical implications (author's transl)].
    Lafille C; Barbier A; Girard J
    Dermatologica; 1979; 159(4):277-89. PubMed ID: 478066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on antigenicity of difluprednate--antigenicity of difluprednate, phototoxicity and photocontact sensitivity of difluprednate ointment and cream].
    Hasegawa T; Ohtani Y; Fujino A; Ochiai T; Uda F; Takahashi K
    J Toxicol Sci; 1985 May; 10(2):155-73. PubMed ID: 4032503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difluprednate for inflammatory eye disorders.
    Mulki L; Foster CS
    Drugs Today (Barc); 2011 May; 47(5):327-33. PubMed ID: 22013563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
    Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
    Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis.
    Kurz PA; Chheda LV; Kurz DE
    Ocul Immunol Inflamm; 2011 Feb; 19(1):84-5. PubMed ID: 21034305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of various vehicles on diclofenac sodium and indomethacin pharmaceutical availability.
    Stozkowska W
    Acta Pol Pharm; 2002; 59(4):253-8. PubMed ID: 12403299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous reactions to imatinib mesylate treated by topical steroid.
    Ujiie H; Shimizu T; Shimizu H
    Am J Hematol; 2005 Mar; 78(3):246. PubMed ID: 15726597
    [No Abstract]   [Full Text] [Related]  

  • 10. Pseudoaldosteronism due to 9-alpha-fluoroprednisolone creams.
    Praga M; Maiz E; Mijares RP; Lopez de Novales E
    Clin Nephrol; 1983 Dec; 20(6):321. PubMed ID: 6641033
    [No Abstract]   [Full Text] [Related]  

  • 11. Difluprednate: more than meets the eye.
    Giacobbe C; Palmisano G; Giovenzana GB; Giovannelli L; Negri R; Masciocchi N
    J Pharm Biomed Anal; 2015 Jan; 102():305-13. PubMed ID: 25459928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles.
    Feldman SR; Sangha N; Setaluri V
    J Am Acad Dermatol; 2000 Jun; 42(6):1017-20. PubMed ID: 10827406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
    Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
    Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyoxyethylene fatty acid esters as potential promotors of transdermal absorption for morphine hydrochloride and sulphate.
    Samczewska G; Piechota-Urbańska M; Kołodziejska J
    Polim Med; 2006; 36(2):17-32. PubMed ID: 17022153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of celecoxib through human skin.
    Yener G; Gönüllü U; Uner M; Değim T; Araman A
    Pharmazie; 2003 May; 58(5):330-3. PubMed ID: 12779049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro release and antiinflammatory activity of topical formulations of ketoprofen.
    Moretti MD; Gavini E; Peana AT
    Boll Chim Farm; 2000; 139(2):67-72. PubMed ID: 10920531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability.
    Wiedersberg S; Naik A; Leopold CS; Guy RH
    Br J Dermatol; 2009 Mar; 160(3):676-86. PubMed ID: 18782322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viscosity of pharmacopeial multimolecular ointment vehicles and pharmaceutical availability of a model therapeutic agent.
    Piechota-Urbańska M; Kołodziejska J; Zgoda MM
    Polim Med; 2007; 37(2):3-19. PubMed ID: 17957945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of bioavailability by lowering of fat content in topical formulations.
    Wirén K; Frithiof H; Sjöqvist C; Lodén M
    Br J Dermatol; 2009 Mar; 160(3):552-6. PubMed ID: 19120336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of biologic availability of active principles contained in galenic forms for cutaneous administration].
    Aiache JM; Aiache S; Guilpain G; Paire M
    Boll Chim Farm; 1977 Feb; 116(2):63-80. PubMed ID: 861080
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.